Immunotherapy after lung cancer surgery for those not getting chemo
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove stage 2 or 3 non-small cell lung cancer, and the surgeon got all the cancer out.
- Your tumor has a protein called PD-L1 at a level of 1% or higher.
- You are not getting chemotherapy after surgery, either because you chose not to or your doctor said you're not healthy enough for it.
- You are at least 18 years old and have recovered from your surgery.
- Your cancer does not have an EGFR mutation or ALK rearrangement.
- You are not pregnant, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the drug cemiplimab before surgery can help treat early-stage non-small cell lung cancer. The goal is to see if it shrinks the tumor or improves outcomes when followed by standard surgery.
This trial tests giving just three cycles of immunotherapy (cemiplimab) without surgery or radiation, specifically for people with early-stage (stage IA) non-small cell lung cancer who cannot have surgery. It aims to see if this shorter treatment can control the cancer with fewer side effects.
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
This trial tests whether giving more immunotherapy after surgery can help people with non-small cell lung cancer who still had some cancer cells left after their first round of immunotherapy and chemotherapy before surgery. It aims to improve outcomes for those whose tumor didn't fully disappear.
This trial tests a drug called cemiplimab, which helps your immune system fight cancer. It is given before and after surgery to try to reduce the chance of the cancer coming back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.